FDA Finalizes Guidance on Alternative Inspection Tools for Drug Manufacturing Facilities

The U.S. Food and Drug Administration has finalized comprehensive guidance establishing a formal framework for using alternative assessment tools to evaluate drug manufacturing facilities identified in pending applications, marking a significant shift toward technology-driven regulatory oversight.

The final guidance, issued September 11, 2025, by the Center for Drug Evaluation and Research (搜索)搜索该词条 and Center for Biologics Evaluation and Research (搜索)搜索该词条, updates the September 2023 draft and fulfills FDA's user fee commitments under PDUFA VII (搜索)搜索该词条 and BsUFA III (搜索)搜索该词条 to incorporate best practices developed during the COVID-19 pandemic.

Risk-Based Framework for Alternative Tools

The FDA employs a risk-based approach to determine when alternative tools may be used in advance of, in lieu of, or to support pre-approval inspections (PAI) and pre-license inspections (PLI). Key factors influencing this determination include:

• The facility's prior inspection history by FDA or trusted foreign regulatory partners, with proposed operations similar to previously inspected activities
• The ability to adequately assess application-specific risks through alternative means
• Urgent public health needs, such as drug shortages or critical public health requirements
• Infeasibility of on-site inspection due to travel limitations, pandemics, natural disasters, or regional instability

In support of Executive Order 14293 on regulatory relief to promote domestic production of critical medicines, the FDA intends to prioritize alternative tools for U.S.-based facilities when appropriate.

Three Primary Alternative Assessment Methods

Remote Regulatory Assessments

Remote regulatory assessments (RRAs) involve examining facilities and records remotely to evaluate compliance with FDA requirements. The framework includes two components:

Mandatory Records Requests: Under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, facilities must provide requested records within specified timeframes. The FDA intends these timeframes to be "reasonable," typically 15 U.S. business days or 30 U.S. business days if translation is required, though potentially shorter in time-sensitive situations.

Voluntary Remote Interactive Evaluations: RIEs use livestreaming, teleconferences, or screen sharing for real-time facility assessment. While participation is voluntary, the FDA cautions that declining may delay application decisions. The agency may coordinate RIE scheduling to coincide with manufacturing operations when visual observation of production processes is needed.

Foreign Regulatory Collaboration

The FDA may leverage inspection reports and information from foreign regulatory authorities under mutual recognition agreements to inform facility assessments. The guidance notes that while FDA has not yet recognized PAIs or PLIs conducted by foreign regulators, the agency may assess inspection information from trusted partners to support application decisions.

Collaborative inspections, where FDA personnel participate remotely alongside foreign inspectors, represent an emerging approach to enhance efficiency and reduce regulatory redundancy across international markets.

Remote Subject Matter Experts

The FDA may supplement on-site inspection teams with remote SMEs when specialized expertise is required and on-site participation is not feasible. The final guidance clarifies that FDA will generally notify facilities in advance when planning to use a remote SME and request written confirmation of the facility's willingness to participate.

The on-site inspection team will begin the inspection before virtually connecting the remote SME and will notify the facility before disconnecting them, improving transparency and accountability in the process.

Implementation Considerations and Consequences

The use of alternative tools remains at FDA's discretion—applicants may not request their use. The guidance applies specifically to drug manufacturing facilities identified in marketing applications and does not cover post-approval inspections, surveillance inspections, follow-up and compliance inspections, or bioresearch monitoring inspections.

Facilities declining to participate in voluntary components like RIEs or remote SME interactions may face practical consequences, including delayed application decisions. Providing insufficient information in response to mandatory records requests may result in complete response letters if FDA cannot confirm that application deficiencies have been satisfactorily addressed.

Timeline and Response Expectations

Facilities are expected to submit responses or corrective actions to FDA within 15 U.S. business days for consideration in the application process. Any responses received afterward may be deferred for assessment in the next application cycle, potentially impacting product launch timelines.

The guidance emphasizes that companies should treat FDA's requests for records, participation in RIEs, or other assessments with the same care and seriousness as traditional inspections, ensuring all responses are accurate, complete, and responsive with thorough documentation.

Regulatory Impact

The formalization of alternative tools reflects FDA's commitment to maintaining operational flexibility while supporting timely facility evaluations and application decisions. The agency views this policy as helping meet user fee goal dates and make timely regulatory decisions in an evolving global regulatory landscape.

The FDA is currently accepting online or written comments on the final Alternative Tools Guidance as the agency continues to refine its risk-based approach to facility evaluation.